SpringWorks Therapeutics, Inc. (SWTX)
NASDAQ: SWTX · Real-Time Price · USD
36.83
-0.61 (-1.63%)
Nov 21, 2024, 12:02 PM EST - Market open
SpringWorks Therapeutics Employees
SpringWorks Therapeutics had 305 employees as of December 31, 2023. The number of employees increased by 78 or 34.36% compared to the previous year.
Employees
305
Change (1Y)
78
Growth (1Y)
34.36%
Revenue / Employee
$444,220
Profits / Employee
-$902,151
Market Cap
2.74B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 305 | 78 | 34.36% |
Dec 31, 2022 | 227 | 51 | 28.98% |
Dec 31, 2021 | 176 | 98 | 125.64% |
Dec 31, 2020 | 78 | 22 | 39.29% |
Dec 31, 2019 | 56 | - | - |
Related Stocks
Company Name | Employees |
---|---|
Amedisys | 19,000 |
Surgery Partners | 13,500 |
Warby Parker | 3,473 |
LivaNova | 2,900 |
HUTCHMED (China) | 1,988 |
TransMedics Group | 584 |
Amicus Therapeutics | 517 |
Xenon Pharmaceuticals | 259 |
SWTX News
- 8 days ago - SpringWorks Therapeutics, Inc. (SWTX) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 9 days ago - SpringWorks Therapeutics to Participate in the Jefferies London Healthcare Conference - GlobeNewsWire
- 9 days ago - SpringWorks Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights - GlobeNewsWire
- 10 days ago - SpringWorks Therapeutics Announces Mirdametinib Data to be Presented at the 2024 Society for Neuro-Oncology (SNO) Annual Meeting - GlobeNewsWire
- 10 days ago - SpringWorks Therapeutics Announces Publication of the Pivotal Phase 2b ReNeu Trial Evaluating Mirdametinib in Adults and Children with NF1-PN in the Journal of Clinical Oncology - GlobeNewsWire
- 14 days ago - SpringWorks Therapeutics Announces Long-Term Efficacy and Safety Data from Phase 3 DeFi Trial of OGSIVEO® (nirogacestat) in Adults with Desmoid Tumors to be Presented at the Connective Tissue Oncology Society (CTOS) 2024 Annual Meeting - GlobeNewsWire
- 16 days ago - SpringWorks Therapeutics to Participate in Guggenheim's Inaugural Healthcare Innovation Conference - GlobeNewsWire
- 16 days ago - SpringWorks Therapeutics Merits A Speculative Buy - Seeking Alpha